Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,184.40up ₹8.90 (0.76%)BSE ₹1,186.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
52-week range of traded prices to 29 Oct 2026
₹835.50Low, 2 Apr 2026₹1,232.10High, 29 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
Zydus Lifesciences board and management
37 filed, newest first.
Aug 2026
11 Aug · Management
May 2026
19 May · Management
Mar 2026
31 Mar · Management
Jan 2026
31 Jan · Management
Sep 2025
5 Sep · Management
Aug 2025
26 Aug · Management
12 Aug · Management
12 Aug · Management
Jun 2025
16 Jun · Management
May 2025
20 May · Management
20 May · Management
Apr 2025
30 Apr · Management
Feb 2025
10 Feb · Management
Jan 2025
Aug 2024
9 Aug · Management
May 2024
17 May · Management
May 2023
18 May · Management
Nov 2022
Aug 2022
May 2022
Jan 2022
21 Jan · Management
Jul 2021
9 Jul · Management
Feb 2021
5 Feb · Management
Jun 2020
19 Jun · Management
Jul 2019
31 Jul · Management
Dec 2018
6 Dec · Management
Mar 2017
May 2016
Dec 2014
4 Dec · Management
Directors of the Company vide circular resolution approved the resignation of Shri Apurva S . Diwanji.
May 2014
May 2011
6 May · Management
Board of Directors at its Meeting held on May 06, 2011 appointed Mr. Nitin Raojibhai Desai as an Additional Director. He is a Non- Executive and Independent Director on the Board w.e.f. May 06, 2011.
Jul 2009
29 Jul · Management
Mr. Homi K. Bilpodiwala, director of the Company who was liable to retire by rotation at the Annual General Meeting of the Company held on July 29, 2009 had not offered himself for re-appointment. In view of the same, Mr. Homi K. Bilpodiwala ceased to be a director of the Company w.e.f. July 29, 2009 after conclusion of the Annual General Meeting.
Apr 2009
29 Apr · Management
Auditor's Report in respect of the audited financial results for the quarter and year ended March 31, 2009. A copy of the Auditor's Report shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
26 Apr · Management
At the Board Meeting of the Company held today i.e. April 26, 2007 necessary resolution has been passed to appoint Mr. Sharvil P. Patel, Director of the Company, as Deputy Managing Director for a period of 5 years from 1st April, 2007 subject to the approval of the Members at the ensuing 12th Annual General Meeting of the Company proposed to be held on 27th July, 2007